Gautier Paux

ADVERSE DRUG REACTION MONITORING: DOING IT THE FRENCH WAY

Nicholas Moore, Gautier Paux, Bernard Bégaud et al. · The Lancet · 1985 · 229 citations

Pharmacy, Clinical Pharmacy, Pharmacology +12

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Sara M. Tolaney, Arlene Chan, Katarína Petráková et al. · Journal of Clinical Oncology · 2023 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

AMEERA-1 phase 1/2 study of amcenestrant, SAR439859, in postmenopausal women with ER-positive/HER2-negative advanced breast cancer

Aditya Bardia, Sarat Chandarlapaty, Hannah M. Linden et al. · Nature Communications · 2022 · 52 citations · Full text

Medicine, Oncology, Pharmacology +17

Development of gatekeeping strategies in confirmatory clinical trials

Alex Dmitrienko, Brian A. Millen, Thomas Brechenmacher et al. · Biometrical Journal · 2011 · 44 citations

Public Health, Biostatistics, Diabetology +10

Phase III (IMROZ) study design: Isatuximab plus bortezomib (V), lenalidomide (R), and dexamethasone (d) vs VRd in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM).

Robert Z. Orlowski, Hartmut Goldschmidt, Michèle Cavo et al. · Journal of Clinical Oncology · 2018 · 32 citations

Medicine, Oncology, Pharmacology +12